STARLING ONCOLOGY INC
STLNNASDAQTrading Snapshot
- Day Range
- $6.35 – $6.69
- 52-Week Range
- $4.85 – $7.13
- Volume (shares)
- 504,403.736
- Avg Volume (shares)
- —
- Shares Outstanding
- 101.9M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $503M
- Last Q Revenue
- $161M
- P/E Ratio
- —
- P/S Ratio
- 1.1x
- EPS (TTM)
- $-0.36
- Dividend Yield
- —
STARLING ONCOLOGY INC
STLNFinancial history unavailable.
StockOtter · stockotter.spaceAbout STARLING ONCOLOGY INC
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (“STLN”) (NASDAQ: STLN) a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2026 f
Oncology Institute (NASDAQ:STLN) Shares Climb 6.1% – Should You Buy?
Shares of Oncology Institute, Inc. (NASDAQ: STLN - Get Free Report) were up 6.1% on Friday. The stock traded as high as $6.56 and last traded at $6.56. Approximately 133,504 shares changed hands during trading, a decline
Cedar Grove Capital Q3 2026 Portfolio Update
During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Gr
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums Physician leaders share clinical insights o
Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Rating
Starling Oncology is rated BUY, supported by strong secular growth and expanding adoption of its oncology managed care services. STLN's revenue model leverages scalable delegation contracts, driving higher PMPM fees, pha
Starling Oncology to Participate in Wells Fargo Healthcare Conference
CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced that